hypoactive


Also found in: Thesaurus.

hy·po·ac·tive

(hī′pō-ăk′tĭv)
adj.
Insufficiently active; underactive: a hypoactive gag reflex.

hy′po·ac′tive·ly adv.
hy′po·ac·tiv′i·ty n.
hy′po·ac′tive·ness n.
American Heritage® Dictionary of the English Language, Fifth Edition. Copyright © 2016 by Houghton Mifflin Harcourt Publishing Company. Published by Houghton Mifflin Harcourt Publishing Company. All rights reserved.
ThesaurusAntonymsRelated WordsSynonymsLegend:
Adj.1.hypoactive - abnormally inactivehypoactive - abnormally inactive      
inactive - not active physically or mentally; "illness forced him to live an inactive life"; "dreamy and inactive by nature"
Based on WordNet 3.0, Farlex clipart collection. © 2003-2012 Princeton University, Farlex Inc.
References in periodicals archive ?
M2 PRESSWIRE-September 5, 2019-: Global Hypoactive Sexual Desire Disorder (HSDD) Treatment Market Analysis Report, 2017-2019 & 2027
(NASDAQ: AMAG) announced today that Vyleesi (bremelanotide injection), a melanocortin receptor agonist indicated for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women, is now commercially available through specialty pharmacies, Avella and BioPlus.
AMAG Pharmaceuticals announced that Vyleesi, a melanocortin receptor agonist indicated for the treatment of acquired, generalized hypoactive sexual desire disorder in premenopausal women, is now commercially available through specialty pharmacies, Avella and BioPlus.
ICU delirium takes two forms, according to Dr Gardiner - hypoactive and agitated.
The Food and Drug Administration has approved bremelanotide (Vyleesi) to treat acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women.
The drug is designed to treat generalized hypoactive sexual desire disorder (HSDD) in premenopausal women.
Biopharmaceutical company Palatin Technologies Inc (NYSE American: PTN) reported on Friday the receipt of marketing approval from the US Food and Drug Administration (FDA) for the New Drug Application (NDA) for Vyleesi (bremelanotide injection) for the treatment of premenopausal women with acquired, generalised hypoactive sexual desire disorder (HSDD), the most common type of female sexual dysfunction in the US.
Hypoactive sexual desire disorder (HSDD) is the most common of the female sexual dysfunctions.
It wasn't an exclamation of surprise, just that I've been suffering with a hypoactive bowel for the last few months.
It wasn't an exclamation of surprise, it's just that I've been suffering with a hypoactive bowel for the last few months.
Bremelanotide is a first-in-class melanocortin 4 receptor agonist developed to treat acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women.
Data included age, gender, type of delirium (hyperactive versus hypoactive), past psychiatric history and/or medications, PICU and hospital length of stay (LOS), history of mechanical ventilation, antipsychotic prescribing, and child psychiatry follow-up after discharge from the PICU.